Subscribe
shutterstock_1155148969_atmosphere1
Atmosphere1 / Shutterstock.com
21 January 2021Big PharmaMuireann Bolger

MSD fails in SCOTUS bid to revive record $2.5bn verdict

A subsidiary of MSD (known as Merck & Co in the US) has failed to revive a record $2.5bn verdict against Gilead Sciences, after the US Supreme Court refused to hear arguments that a patent was improperly invalidated.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
MSD antibiotic patent obvious, says Federal Circuit
27 October 2017   Merck Sharp & Dohme (MSD) has suffered a loss at the US Court of Appeals for the Federal Circuit, after the court affirmed an earlier finding of obviousness.
Americas
MSD petitions SCOTUS over $2.5bn patent verdict
28 September 2020   MSD subsidiary Idenix has urged the US Supreme Court to review the overturning of a record $2.5 billion verdict against Gilead Sciences.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
MSD antibiotic patent obvious, says Federal Circuit
27 October 2017   Merck Sharp & Dohme (MSD) has suffered a loss at the US Court of Appeals for the Federal Circuit, after the court affirmed an earlier finding of obviousness.
Americas
MSD petitions SCOTUS over $2.5bn patent verdict
28 September 2020   MSD subsidiary Idenix has urged the US Supreme Court to review the overturning of a record $2.5 billion verdict against Gilead Sciences.

More on this story

Americas
MSD antibiotic patent obvious, says Federal Circuit
27 October 2017   Merck Sharp & Dohme (MSD) has suffered a loss at the US Court of Appeals for the Federal Circuit, after the court affirmed an earlier finding of obviousness.
Americas
MSD petitions SCOTUS over $2.5bn patent verdict
28 September 2020   MSD subsidiary Idenix has urged the US Supreme Court to review the overturning of a record $2.5 billion verdict against Gilead Sciences.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility